Contract facts
NONENo full NAICS 325414 intel page yet. Browse NAICS intelligence
PRODUCTION OF THERAPEUTIC IN SUPPORT OF NATIONAL EMERGENCY RESPONSE TO CORONAVIRUS 2019 (COVID-19):THE GOVERNMENT IS PU… is a federal NONE award for Department of Defense (DOD) held by Regeneron Pharmaceuticals, Inc. Estimated value $5.6B ($2.9B obligated). Current period of performance ends Jul 31, 2022. Last award drew 1 bidder. Place of performance: TARRYTOWN, NY. Related solicitation W15QKN21R0047.
PRODUCTION OF THERAPEUTIC IN SUPPORT OF NATIONAL EMERGENCY RESPONSE TO CORONAVIRUS 2019 (COVID-19):THE GOVERNMENT IS PURCHASING 2,650,000 DOSES OF THE EMERGENCY USE AUTHORIZATION (EUA) THERAPEUTIC.
Recompete timing
PublicCurrent PoP ended Jul 31, 2022 (1502 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordRegeneron Pharmaceuticals, Inc — $-7,005,694 obligated across 6 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract W15QKN21C0014?
W15QKN21C0014 (Production of therapeutic in support) is a W6qk Acc-Pica award with an estimated value of $5.6B, currently held by Regeneron Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is W15QKN-21-C-0014?
W15QKN-21-C-0014 is the dashed form of PIID W15QKN21C0014 (Production of therapeutic in support), held by Regeneron Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded W15QKN21C0014?
W6qk Acc-Pica awarded W15QKN21C0014 to Regeneron Pharmaceuticals, Inc.
Who is the incumbent on W15QKN21C0014?
Regeneron Pharmaceuticals, Inc is the incumbent with $-7,005,694 across 6 related awards in SCOUT’s public footprint. The current period of performance ends Jul 31, 2022.
When does Regeneron Pharmaceuticals, Inc’s W15QKN21C0014 come up for recompete?
SCOUT tracks a period-of-performance end of Jul 31, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Seen enough? Run one full capture cycle on W15QKN21C0014 — $90 for 90 days.
This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.
$1/day · one payment · no subscription
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.